



Thursday, May 21

09:00 - 10:00
Sala Pegaso 1

>>> Keynote Lectures

Chair: Annamaria Cattelan (Padova)

09.00 - 09.30 **Scaling Up PrEP and Its Effects on the HIV Epidemic: From Modelling Evidence to Public Health Impact**

Valentina Cambiano, London
UK

The efficacy of Pre-Exposure Prophylaxis (PrEP; whether oral or as injectable) is undeniable. Modelling studies have consistently demonstrated that the availability of PrEP can substantially accelerate the decline in new infections when combined with existing prevention tools such as testing and treatment and viral suppression in those living with HIV. They have suggested as well that the introduction of oral PrEP in populations at risk of HIV offers value for money, however for injectable PrEP to be cost-effective in most high-income countries the current cost of injectables needs to decline substantially. Now, real-world data have confirmed that scale up of PrEP leads to substantial reductions in HIV incidence, however implementation programmes indicated that real-world impact depends not only on PrEP efficacy and uptake but also on equitable access, sustained adherence, and integration with sexual health services. To achieve the full public health benefit predicted by models, high-income countries must address disparities in PrEP awareness and use, ensure service reliability and friendliness.

Chair: Raffaele Bruno (Pavia)

09.30 - 10.00 **HBV and HDV cure: shaping the future**

Pietro Lampertico, Milano

The field of novel antiviral therapies for HBV and HDV is evolving rapidly. In 2026, the first phase III study in HBV using functional cure (FC) as the primary endpoint will be presented and published. A finite 24-week course of antisense oligonucleotide (ASO) therapy has demonstrated significant functional cure rates 24 weeks after discontinuation of all treatments, including nucleos(t)ide analogues (NUCs). In parallel, several innovative anti-HDV strategies are under development. Currently, four to five phase III trials are ongoing, based on two distinct approaches: monoclonal antibody (mAb) monotherapy or mAb combined with small interfering RNA (siRNA). Preliminary data suggest that these regimens may offer greater efficacy than long-term bulevirtide (BLV) monotherapy, which remains the only approved treatment for HDV to date.

10:05 - 11:05

Sala Pegaso 1

>>> Satellite Symposium

With an unrestricted educational grant from Gilead Sciences

Shaping the future of HIV treatment and prevention: innovation that meets evolving individuals' needs

This symposium aims to provide a comprehensive overview of how innovation in HIV prevention and treatment can be meaningfully aligned with the evolving needs of individuals. Although remarkable progress has been made in reducing new infections and improving Long-Term outcomes for people living with HIV, significant challenges remain in ensuring that prevention tools and therapeutic strategies are truly accessible, acceptable, and sustainable for the diverse populations they are designed to serve. The session is structured around the natural continuum of HIV care. The symposium will examine unmet needs in prevention, focusing on how Long-Acting approaches may help overcome persistent barriers to uptake, adherence, and persistence, particularly among individuals not adequately reached by current daily oral options. Next, the program focuses on therapeutic optimization in routine clinical practice, highlighting how modern regimens can offer durable efficacy and forgiveness, excellent Long-Term safety, and low interaction potential—ultimately supporting Long Term wellbeing across heterogeneous populations. It then looks ahead to future therapeutic pathways, exploring how emerging oral and Long-Acting strategies may further enhance personalization of care by accommodating individual preferences, clinical complexities, and lifestyle considerations. A closing moderated discussion will integrate insights from all three lectures, with the aim of connecting these elements into a coherent vision: one in which innovation supports a genuinely individual-centered approach to HIV prevention and treatment, enhancing both clinical outcomes and quality of life across the continuum of care.

Chairs: Antonella Castagna (Milano), Giuseppe Nunnari (Catania)
10.05 - 10.20 Rethinking HIV prevention: Long-Acting protection to address individuals' needs

Andrea Antinori, Roma

10.20 - 10.35 Optimizing today's therapy: meeting diverse patient needs for Long-Term benefits

Giulia Carla Marchetti, Milano

10.35 - 10.55 Shaping the future: oral and Long-Acting options to address patient's needs
Onyema Ogbuagu, New Haven
USA
10.55 - 11.05 Connecting the Dots: the individual at the center of HIV care

Discussants:

Andrea Antinori, Roma

Antonella Castagna, Milano

Giulia Carla Marchetti, Milano

Giuseppe Nunnari, Catania

Onyema Ogbuagu, New Haven
USA

11:10 - 12:10

Sala Pegaso 1

>>> Symposium

Optimizing antiretroviral therapy in Italy: innovation, implementation, and impact

Despite significant advances in antiretroviral therapy (ART), optimizing treatment strategies for people with HIV (PWH) remains a dynamic challenge. The evolving therapeutic landscape now includes not only highly effective daily oral regimens but also innovative Long-Acting formulations that have the potential to transform adherence, PWH satisfaction, and healthcare delivery. However, real-world data, national policy frameworks, and implementation barriers continue to influence the pace of adoption and the equity of access to these new therapeutic options. This symposium brings together national experts to provide a comprehensive overview of the current Italian scenario and global trends in ART. The session will address the present "snapshot" of antiretroviral use and trends in Italy, discuss opportunities and challenges in scaling up Long-Acting therapies, and present clinical experiences in managing complex and unconventional treatment cases. Through these discussions, the symposium aims to stimulate critical reflection on how to best integrate innovation into daily practice and optimize Long-Term outcomes for PWH.

Chairs: Sergio Lo Caputo (Foggia), Annalisa Perziano (Torino)

11.10 - 11.25 The Italian Landscape of Antiretroviral Therapy
Andrea De Vito, Sassari
11.15 - 11.40 Long-Acting ART: Barriers to Adoption and Paths to Scale
Silvia Nozza, Milano
11.40 - 11.55 Managing Complex Cases: Unconventional Use of Antiretrovirals Treatments
Andrea Giacomelli, Milano
11.55 - 12.10 Discussion
11:10 - 12:10
Sala Pegaso 2
>>> Symposium
Liver Disease at the Viral–Metabolic Interface: What Matters Now

Viral and metabolic determinants of liver injury increasingly coexist and interact, reshaping the epidemiology, pathogenesis, and management of liver disease. Despite major advances in prevention, acute viral hepatitis continues to occur both sporadically and within outbreaks in Europe, while chronic infections and metabolic dysfunction sustain a growing burden of steatosis, fibrosis, and hepatocellular carcinoma. This session explores current priorities at the viral-metabolic interface, from the evolving epidemiology of acute hepatitis to breakthroughs in HBV cure research, the burden and emerging treatment options for MASLD in people with HIV, and the risk and clinical implications of HBV reactivation with evolving antiretroviral strategies. Through an integrated clinical and virological lens, the discussion will highlight mechanisms, therapeutic opportunities, and translational gaps that define what matters now in liver disease.

Chairs: Anna Maria Geretti (Roma), Giovanni Mazzola (Palermo)
11.10 - 11.25 Epidemiologic Trends in Acute Viral Hepatitis in Europe
Maria Elena Tosti, Roma
11.25 - 11.40 MASLD in People with HIV: Metabolic–Inflammatory Crosstalk and Clinical and Therapeutic Aspects
Giovanni Guaraldi, Modena
11.40 - 11.55 HBV Reactivation in the Context of HBV-inactive ART
Massimo Puoti, Milano
11.55 - 12.10 Discussion
11:10 - 12:10
Sala Antares
>>> Oral Communications
11:10 - 12:10
Sala Mizar
>>> Short Communications

**12:15 - 13:15****Sala Pegaso 1**

>>> Satellite Symposium

With an unrestricted educational grant from ViiV Healthcare

Is viral suppression enough? New opportunities for People Living with HIV (PWH)

Given the high level of effectiveness of today's antiretroviral therapies, it is crucial to look beyond viral suppression and place broader dimensions of health for people living with HIV (PWH) at the centre. This Symposium aims to focus on three key areas: the value of adherence to ART and the potential consequences of non-adherence; the clinical and psychosocial benefits that Long-Acting therapies can provide; and organizational models that, through target restructuring, have already been shown to concretely improve the quality of life for many people. Exploring the role of adherence is essential not only for virologic control but also because non-adherence carries significant risks for individual health and public health alike. Long-Acting therapies can reduce the daily treatment burden, offer greater discretion, potentially improve the care experience and have positive impacts on psychosocial well-being. It is important to assess these benefits in light of the real needs of PWH and any barrier to access. Finally, there are organizational implementation models that – by redesigning care pathways, integrating hospital and community services and developing supportive tools – have extended the benefits of therapeutic innovations to a larger number of people, resulting in measurable improvements in quality of life. This Symposium seeks to share these experiences to promote the adoption of sustainable, person-centered solutions.

Chairs: Vincenzo Esposito (Napoli), Giuseppe Nunnari (Catania)
12.15 - 12.20 Introduction
 Vincenzo Esposito, Napoli
 Giuseppe Nunnari, Catania
12.20 - 12.35 Adherence matters: from daily doses to lifelong continuity
 Angelo Roberto Raccagni,
 Milano
12.35 - 12.50 Beyond the pills: Long-Acting clinical and quality of life outcomes?

Roberto Rossotti, Verona

12.50 - 13.05 People-first pathways: organizational models for integrated HIV care
 Simona Di Giambenedetto,
 Roma
13.05 - 13.15 Q&A led by the chairs and Take-home messages
 Vincenzo Esposito, Napoli
 Giuseppe Nunnari, Catania
12:15 - 13:15**Sala Pegaso 2**

>>> Expert Meeting

With an unrestricted educational grant from Gilead Sciences

Hepatitis/HIV screening strategies, early diagnosis, and HDV antiviral treatment

Hepatitis D Virus and Cancer risk: the race from early detection to early treatment Chronic hepatitis D remains the most aggressive form of viral hepatitis, with a rapid progression to cirrhosis and hepatocellular carcinoma. Despite this burden, HDV is still underdiagnosed, particularly among migrants and underserved populations, where gaps in screening and linkage to care persist. This Meet the Expert session will address the urgent need for systematic testing, early diagnosis, and timely initiation of effective therapies. By integrating epidemiology, screening strategies, and advances in antiviral treatment, the session aims to provide practical guidance to reduce the clinical impact of HDV and improve patient outcomes.

Chairs: Franco Maggiolo (Fabro TR), Massimo Puoti (Milano)
12.15 - 12.35 Hepatitis and HIV testing: addressing care gaps for migrants and underserved. The "Test in the City" experience

Paolo Meli, Bergamo

12.35 - 12.55 The silent threat of HDV: the critical need for early diagnosis
Annamaria Cattelan, Padova
12.55 - 13.15 BLV for early HDV treatment: turning the tide on the most aggressive viral hepatitis
Pietro Lampertico, Milano
12:15 - 13:15
Sala Pegaso 2

>>> Oral Communications

12:15 - 13:15
Sala Antares

>>> Expert Meeting

12:15 - 13:15
Sala Mizar

>>> Oral Communications

14:00 - 15:00
Sala Pegaso 1

>>> Symposium

Quenching or enhancing immune response in HIV care and cure

Since the beginning of HIV epidemic, immunopathogenesis has been considered a key factor for the understanding of the disease, but immunological therapeutical approaches are not been reliable until now. The early dysregulation of natural and specific immune response and inflammation are difficult to control, even in antiretroviral treated PWH. In the symposium, recent approaches will be discussed focussing on high specific, novel molecular target therapies combined or not with modern ART.

Chairs: Miriam Lichtner (Roma), Giulia Carla Marchetti (Milano)
14.00 - 14.15 (HIV-1)-specific broadly neutralizing monoclonal antibodies (bNAbs) for HIV care and cure: perspectives and hopes
Gabriella Scarlatti, Milano
14.15 - 14.30 T-reg cells in the immunopathogenesis of HIV: Clinical implications
Chiara Agrati, Roma
14.30 - 14.45 Molecular targets to manage inflammation
Andrea Cossarizza, Modena
14.45 - 15.00 Discussion

14:00 - 15:00**Sala Pegaso 2**

>>> Symposium

Intersectionality among cancer and ageism among PWH

As people with HIV (PWH) live longer due to effective antiretroviral therapy, ageing-related conditions such as cancer are becoming leading causes of morbidity and mortality. This symposium addresses the intersection between ageing, oncological burden, and social determinants such as ageism. Discussions will focus on priorities for cancer prevention and early detection, barriers to accessing standard treatments and clinical trials, and the impact of stigma and age-related bias on health outcomes in older PWH. Promoting an integrated, equitable approach to care is essential to improve longevity and quality of life in this growing population.

Chairs: Antonella Cingolani (Roma), Ada Moznich (Milano)
14.00 - 14.15 Cancer burden in PWH: priorities for prevention and care
Lene Ryom, Copenhagen DK
14.15 - 14.30 Treatment challenges, access to standard treatments, and trial inclusion: the paradigm of HIV-associated lymphoma
Alessandro Re, Brescia
14.30 - 14.45 Missed opportunities: the impact of ageism on people aging with HIV
Nicoletta Policek, Bruxelles BE
14.45 - 15.00 Discussion
14:00 - 15:00**Sala Antares**

>>> Oral Communications

14:00 - 15:00**Sala Mizar**

>>> Short Communications

15:05 - 16:05**Sala Pegaso 1**

>>> Satellite Symposium

With an unrestricted educational grant from MSD Italy
Therapeutic management of PWH: from current clinical practice to future perspectives

The purpose of this session is to explore how the therapeutic management of people living with HIV is evolving, from current clinical practice toward future treatment strategies. Particular attention will be given to the growing burden of comorbidities, especially cardiometabolic ones, and to the need for early, proactive intervention to prevent progression and Long-Term complications. Within this context, next-generation NNRTIs will be discussed as a key component of antiretroviral regimens, thanks to their favorable metabolic profile and their potential role in improving cardiometabolic health. In parallel, the session will address the emerging role of NNRTIs as a pillar of the new generation of ART, and how these innovations can support a more personalized, patient-centered approach to the care of people living with HIV.

Chairs: Annamaria Cattelan (Padova), Andrea Gori (Milano)
15.05 - 15.25 Comorbidities and HIV: why we need to act now
Paolo Maggi, Enna
15.25 - 15.45 Next-generation NNRTIs: a key ally in managing cardiometabolic comorbidities
Leonardo Calza, Bologna

15.45 - 16.05 New frontiers in HIV management: NRTTIs as a pillar of next-generation ART

Andrea Calcagno, Novara

15:05 - 16:05

Sala Pegaso 2

>>> Oral Communications

15:05 - 16:05

Sala Antares

>>> Expert Meeting

With an unrestricted educational grant from Menarini

Antibiotic therapy: microbiological and clinical challenges for the treatment of in- and out- patients

Bacterial infections represent the major emergency in the field of infectious diseases. This is due to the increased incidence of nosocomial infections, which places a burden on care in terms of mortality and disability and on the economy in terms of healthcare costs. The availability of new antimicrobial therapies is changing the management of gram-negative infections by offering new therapeutic opportunities for the management of increasingly "difficult" strains. On the other hand, from the point of view of antibiotic sensitivity, and antibiotic PK the availability of Long-Acting drugs is changing the treatment strategies for gram-positive infections, reducing the duration of hospitalisations and changing the profile of outpatient antibiotic therapy.

Chairs: Antonio Cascio (Palermo), Giusy Tiseo (Pisa)

15.05 - 15.25 How to manage nosocomial infections caused by Carbapenemases-Producing Enterobacteriaceae (CPE)

Marco Falcone, Pisa

15.25 - 15.45 Long-Acting antibiotics in outpatient antibiotic therapy: clinical and real-life evidences

Massimo Puoti, Milano

15.45 - 16.05 Discussion led by the chairs

Antonio Cascio, Palermo
 Giusy Tiseo, Pisa

15:05 - 16:05

Sala Mizar

>>> Oral Communications

16:10 - 17:10

Sala Pegaso 1

>>> Symposium

Cardiovascular Kidney Metabolic (CKM) syndrome: a new framework to manage metabolic health

Cardiovascular-Kidney-Metabolic (CKM) syndrome provides a framework to understand the interconnected risks of cardiovascular disease, kidney dysfunction, and metabolic disorders in people living with HIV. HIV infection, antiretroviral therapy, and chronic inflammation can amplify these risks, making early identification and integrated management essential. This approach emphasizes holistic, multidisciplinary strategies to optimize Long-Term health and reduce the burden of cardiometabolic complications in this population.

Chairs: Paolo Bonfanti (Monza), Manuela Ceccarelli (Enna)

16.10 - 16.25 Introduction: Frameworiking CKM syndrome

Giovanni Guaraldi, Modena



Talk show

16.25 - 16.40 Balancing the Scales: Can GLP-1RAs Redefine Weight Management in People Living with HIV? *Nicola Squillace, Monza*

Focusing on obesity/weight gain (focusing on GLP-1RA)

16.40 - 16.55 Breaking the Cycle: Addressing Bone Loss in People Living with HIV *Maria Mazzitelli, Roma*

Focusing on Bone Health

16.55 - 17.10 Healthy Hearts, Balanced Sugar: Navigating Cardiometabolic Risks in HIV *Vincenzo Spagnuolo, Milano*

Focusing on cardiovascular health and diabetes

16:10 - 17:10

Sala Pegaso 2

>>> Oral Communications

16:10 - 17:10

Sala Antares

>>> Oral Communications

16:10 - 17:10

Sala Mizar

>>> Short Communications

17:15 - 18:40

Sala Pegaso 1

>>> Oral Communications

17:15 - 18:40

Sala Pegaso 2

>>> Oral Communications

17:15 - 18:40

Sala Antares

>>> Oral Communications

17:15 - 18:40

Sala Mizar

>>> Oral Communications